Seer Inc - Asset Resilience Ratio
Seer Inc (SEER) has an Asset Resilience Ratio of 49.99% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SEER current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Seer Inc's Asset Resilience Ratio has changed over time. See SEER total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Seer Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Seer Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $154.26 Million | 49.99% |
| Total Liquid Assets | $154.26 Million | 49.99% |
Asset Resilience Insights
- Very High Liquidity: Seer Inc maintains exceptional liquid asset reserves at 49.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Seer Inc Industry Peers by Asset Resilience Ratio
Compare Seer Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Seer Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Seer Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 53.37% | $195.66 Million | $366.60 Million | -11.66pp |
| 2023-12-31 | 65.03% | $283.73 Million | $436.27 Million | -10.39pp |
| 2022-12-31 | 75.43% | $368.03 Million | $487.93 Million | +44.40pp |
| 2021-12-31 | 31.02% | $167.26 Million | $539.14 Million | +8.80pp |
| 2020-12-31 | 22.22% | $98.28 Million | $442.32 Million | -51.29pp |
| 2019-12-31 | 73.51% | $68.53 Million | $93.24 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $33.70 Million | -- |
About Seer Inc
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab fo… Read more